References
- 1. De Waha S, Eitel I, Desch S, et al. Impact of multivessel coronary artery disease on reperfusion success in patients with ST elevation myocardial infarction: A substudy of the AIDA STEMI trial. Eur Heart J Acute Cardiovascular Care. 2018;7:28-37. doi: 10.1177/2048872615624240.10.1177/204887261562424026691729
- 2. Lekston A, Tajstra M, Gąsior, et al. Impact of multivessel coronary disease on one-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Kardiol Pol. 2011;69:336-343.
- 3. Batra MK, Rasool SI, Solangi BA, et al. Multivessel disease as a prognostic marker in patients presenting for primary percutaneous coronary intervention. J Ayub Med Coll Abbottabad. 2018;30:534-538.
- 4. De Luca G, Gibson M, Cutlip D, et al. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. Arch Cardiovasc Dis. 2013;106:155-161. doi: 10.1016/j.acvd.2012.12.007.10.1016/j.acvd.2012.12.00723582677
- 5. Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312:2019-2027. doi: 10.1001/jama.2014.15095.10.1001/jama.2014.1509525399277
- 6. Tarantini G, Napodano M, Gasparetto N, et al. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis. 2010;21:78-86. doi: 10.1097/MCA.0b013e328335a074.10.1097/MCA.0b013e328335a07420071979
- 7. De Luca G, Parodi G, Sciagrà R, et al. Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty. Atherosclerosis. 2014;234:244-248. doi: https://doi.org/10.1016/j.atherosclerosis.2014.02.031.10.1016/j.atherosclerosis.2014.02.03124685816
- 8. Widimsky P, Holmes DR Jr. How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease? Eur Heart J. 2011;32:396-403. doi: 10.1093/eurheartj/ehq410.10.1093/eurheartj/ehq410303833521118854
- 9. Greshlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease. J Am Coll Cardiol. 2015;65:963-972. doi: 10.1016/j.jacc.2014.12.038.10.1016/j.jacc.2014.12.038435905125766941
- 10. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2019;40:87-165. doi: https://doi.org/10.1093/eurheartj/ehy394.10.1093/eurheartj/ehy39430165437
- 11. Mrdovic I, Savic L, Lasica R, et al. Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. Eur Heart J Acute Cardiovascular Care. 2014;3:56-66. doi: 10.1177/2048872613514013.10.1177/2048872613514013393277724562804
- 12. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-1716. doi: 10.1093/eurheartj/ehm184.10.1093/eurheartj/ehm18417556348
- 13. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115-1123. doi: 10.1056/NEJMoa1305520.10.1056/NEJMoa130552023991625